[PDF] Top 20 Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal.

... lipid- lowering compounds (statins), antiplatelet agents (aspirin), blockers of the renin-angiotensin system (angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists) or various ... Voir le document complet

... SIRT1. In fact, metformin has been shown to prevent the hyperglycaemia-induced reduction of SIRT1 protein levels while ameliorating glucose uptake into podocytes and decreasing glomerular filtration ... Voir le document complet

... management of type 2 ...active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 inhibitors exert slightly less pronounced HbA1c reduction than ... Voir le document complet

... the Diabetes Prevention Program Coordinating Center, Biostatistics Center, George Washington University, Rockville, ...comments of Drs. Scheen (1) and Buchanan (2) regarding our article (3), which ... Voir le document complet

... for type 2 diabetes mellitus, the mechanisms underlying the plasma glucose level‐lowering effects of metformin (1,1‐ dimethylbiguanide) still remain incompletely ... Voir le document complet

... improvements in skeletal muscle mitochondrial function have already been studied in healthy subjects [28] and in insulin resistant patients, including type 2 diabetes mellitus ... Voir le document complet

... not a direct measurement of AGE and it may be influenced by other fluorophores in the skin; neverthe- less, SAF does correlate with pentosidine, a common AGE, in skin ...with ... Voir le document complet

... the A and B zones, while only 0%, 9% and 0% of values are within the C, D and E zones, ...overestimate glucose levels during exercise compared with blood glucose concentrations, especially ... Voir le document complet

... Society of Echocardiography guidelines ...Doppler of mitral as well as tricuspid inflow velocities, including early (E) and atrial (A) waves, were ...measures of myocardial systolic, early ... Voir le document complet

... weeks of treatment showed that voglibose (0 . 2 mg three times a day) reduced the risk of patients with impaired glucose tolerance developing type 2 diabetes by 40 ... Voir le document complet

... preservation of B-cell function and protection from type 2 diabetes persisted 8 months after interruption of troglitazone in the recent TRIPOD trial, 5 a finding that ... Voir le document complet

... However, in a case-control study performed in Taiwan, patients who have OA and T2DM receiving combination NSAIDs and metformin therapy had lower joint replacement surgery rates than those without ... Voir le document complet

... has a number of strengths including size (high statistical power even after risk factor stratification), prospective design (reducing the risk of reverse causation bias), and inclusion of well ... Voir le document complet

... PCSK9 a permis une restauration de l’expression du LDLR à hauteur de 30% caractérisée par une internalisation de plus de 80% des particules de LDL (Shan et ...peptide a été capable de restaurer à 100% ... Voir le document complet

... unique in that they increase glucose excretion, independent of insulin secretion, by inhibiting the renal reabsorption of glucose, inducing glucosuria 3 ...improve glucose ... Voir le document complet

... are of great clinical ...independently of potential cofounders and may represent a therapeutic option in slightly dyslipidemic ...effect in primary prevention regarding CHD risk ... Voir le document complet

... prescribe a GLP-1 RA, another question arises: which one should be considered as the best option ? Indeed, an increasing number of GLP-1 RAs are already on the market (exenatide, exenatide LAR, liraglutide, ... Voir le document complet

... Second-line agents are diverse and increasingly numerous. [3] Currently, in most countries, the clinician has the choice between sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors ... Voir le document complet

... hyperactivation of the EC tone in obesity. Since the early 1990s, a number of genetic polymorphisms in the genes and proteins of the EC system have been characterized ...toward ... Voir le document complet

... as a PKC- target involved in the negative modulation of the insulin signal ...[92]. In addition, after overexpression of human IRS1, Luo et ...Ser1223 a positive regulatory role ... Voir le document complet